Novartis AG is nearing a deal to acquire Avidity Biosciences Inc.; terms were not disclosed. The potential acquisition is a material M&A event for the biotech, likely to lift Avidity's shares and signal Novartis's strategic push into the biotech pipeline, with expected sector reaction and possible regulatory/antitrust review.
Novartis AG is nearing a deal to acquire Avidity Biosciences Inc.; terms were not disclosed. The potential acquisition is a material M&A event for the biotech, likely to lift Avidity's shares and signal Novartis's strategic push into the biotech pipeline, with expected sector reaction and possible regulatory/antitrust review.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
